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Introduction {#sec1}
============

Rett syndrome is a disease associated with loss of function mutations in the gene MECP2, which was originally identified as encoding a methylated DNA binding protein ([@bib3], [@bib21]). Patient symptoms include microcephaly, intellectual disability, facial dysmorphia, and seizure activity ([@bib2]). Studies in murine models recapitulate many of the patient phenotypes and have recently identified a role for Mecp2 particularly in inhibitory neurons ([@bib33]). These studies demonstrated that loss of MECP2 can lead to defects in transcription ([@bib4], [@bib12]), dendritic branching ([@bib41]), nuclear size ([@bib3]), and AKT signaling ([@bib13]).

MECP2 has also been described as a transcription factor with specific targets ([@bib4], [@bib41]), and more broadly as either a transcriptional activator ([@bib13]) or repressor ([@bib6], [@bib24]). However, despite decades of research on MECP2, it is still unclear how mutations in this protein lead to patient symptoms ([@bib3], [@bib18]). To confirm findings made in other models and further study these in a human system, some have turned to modeling Rett syndrome *in vitro* by taking advantage of disease-in-a-dish approaches. This involves making human induced pluripotent stem cells (hiPSCs) from patient somatic cells, or using genome engineering to introduce mutations into wild-type (WT) human pluripotent stem cells. In the current study, we also sought to mitigate the effect of genetic background and variability of differentiation by taking advantage of several isogenic lines of hiPSCs that either express the WT allele or the mutant allele leading to cells that express or lack MECP2 ([@bib32]). This allowed for detailed molecular analyses of hiPSCs, neural progenitor cells (NPCs), and neurons with and without MECP2 under the same genetic background. In comparing neurons from Rett patients as well as those with *MECP2* silenced by small interfering RNA (siRNA), it is clear that loss of MECP2 leads to induction of P53 and senescence, potentially opening an avenue of investigation for this intellectual disability syndrome.

Results {#sec2}
=======

A Human Model of Rett Syndrome *In Vitro* {#sec2.1}
-----------------------------------------

Cognizant of the fact that differentiation from hPSCs is highly variable across individual lines, culture conditions, and time, we developed an isogenic model to study Rett syndrome *in vitro* to remove the confound of genetic background ([@bib32]). Because female patients with Rett syndrome are usually heterozygous for mutant alleles of *MECP2*, fibroblasts isolated from these patients display a mosaic pattern where roughly half the cells express either the mutant or WT allele. This is shown in [Figure 1](#fig1){ref-type="fig"}A, where fibroblasts isolated from two patients with distinct mutant alleles of *MECP2* (R982 and R567) showed that roughly half the cells expressed MECP2 while the other half lacked detectable amounts of this protein. Patient descriptions are provided in [Figure S1](#mmc1){ref-type="supplementary-material"}. Reprogramming to iPSCs using a small set of transcription factors has been shown to happen at the clonal level, such that individual reprogramming events in single fibroblasts generate isolated hiPSC clones ([@bib38]). Therefore, reprogramming of mosaic fibroblast cultures from two different patients generated single hiPSC clones that either expressed MECP2 protein or lacked it ([Figure 1](#fig1){ref-type="fig"}B) (method described in a previous study; [@bib28]). In addition, our work and that of others has shown that under standard conditions, the inactive X chromosome in human fibroblasts does not reactivate upon reprogramming to the pluripotent state ([@bib32]), which is distinct from murine reprogramming ([@bib17]).Figure 1Generation of the Isogenic Model of Rett Syndrome *In Vitro*(A) Fibroblasts isolated from Rett syndrome patients (R982 and R567) heterozygous for MECP2 mutations exhibit a mosaic pattern of MECP2 expression due to random XCI.(B) Multiple isogenic hiPSC lines were produced from patient 982 with a typical Yamanaka protocol yielding individual isogenic clones with and without MECP2 expression from the same patient, as judged by NANOG and OCT4 staining.(C) Specification of hiPSCs derived from patient 982 toward neural progenitor cells yielded homogeneous cultures of NPCs with and without MECP2.(D) Terminal differentiation of NPCs derived from patient 982 toward neurons and glia by growth factor withdrawal as measured by immunostaining for MAP2 and GFAP.(E) MECP2+ and MECP2− hiPSCs and neurons were assayed by western blot with antibodies that recognize the active forms of Akt and its downstream target S6.(F) Sholl assay of dendritic complexity was performed on WT versus MUT neurons derived from patient 982.^∗^p \< 0.05 according to Student\'s t test. Bar graphs represent means ± SEM. Scale bars on images indicate 10 μm.

Thus, we were able to create multiple lines of hiPSCs with and without MECP2 from individual patients and thereby control for differences in genetic background (shown in [Figure 1](#fig1){ref-type="fig"}B are clones made from patient 982; clones from 567 look similar). The hiPSCs generated from fibroblasts of both patients appeared to be unaffected by the lack of MECP2, expressed all appropriate markers, and successfully generated teratomas upon injection into the testes of immunocompromised mice, consistent with previous hiPSC models for loss of MECP2 ([Figure S2](#mmc1){ref-type="supplementary-material"}A) ([@bib5], [@bib10]). Lack of MECP2 in patient-derived cells and specificity of antibody was also confirmed by western blot ([Figure S2](#mmc1){ref-type="supplementary-material"}B).

Importantly, we never observed reactivation of the silenced X chromosome that would have resulted in re-expression of the WT allele of *MECP2* in any cultures regardless of differentiation status or passage. This is consistent with previous data showing that, despite evidence for erosion of isolated portions of the silenced X chromosome ([@bib22]), many portions of the inactivated X remain silenced even through reprogramming or differentiation ([@bib25], [@bib32]). To measure the effect of any potential XCI erosion, we performed a DNA methylation analysis on the X chromosome on the lines from patient 982. This analysis showed that while some erosion of XCI was detectable across the X chromosome, there was not a significant difference between any of the lines ([Figure S3](#mmc1){ref-type="supplementary-material"}A), and methylation at the *MECP2* locus specifically was unchanged between the lines ([Figure S3](#mmc1){ref-type="supplementary-material"}B).

As Rett syndrome primarily afflicts the nervous system and MECP2 is most highly expressed in neurons, we first generated NPCs from all of the hiPSCs lines following standard protocols ([@bib26]). Across at least two lines per patient with and without MECP2, we measured the rate of neuralization, the morphology of NPCs, and expression of typical marker genes. We were unable to detect consistent differences in these properties between multiple clones of both WT and MECP2 null lines derived from both patients ([Figures 1](#fig1){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}C). Furthermore, the growth rate of NPCs with and without MECP2 was not consistently different in NPCs made from either patient ([Figure S2](#mmc1){ref-type="supplementary-material"}D). Next, the NPCs were further differentiated by a non-directed differentiation approach that yields both neurons and glia (growth factor withdrawal; [@bib26]) ([Figure 1](#fig1){ref-type="fig"}D). All NPCs from both patients produced neurons and glia at the same rate ([Figures S2](#mmc1){ref-type="supplementary-material"}E and S2F).

Previous studies have also shown that loss of MECP2 in neurons can lead to a decrease in AKT signaling ([@bib13]). A similar pattern was observed here in mutant neurons generated from Rett patient hiPSCs as measured by phosphorylation of AKT and S6, while hiPSCs themselves did not seem to be affected by loss of MECP2 ([Figure 1](#fig1){ref-type="fig"}E). Dendritic complexity has been shown extensively to be reliant on MECP2 expression in various models of Rett syndrome, and we found a statistically significant decrease in complexity in neurons made in the absence of MECP2 by Sholl assay ([Figure 1](#fig1){ref-type="fig"}F). In addition, we observed qualitative differences in basic neuronal morphology between WT and mutant neurons, where the neurons lacking MECP2 had shorter, thicker processes, and their soma was not as well defined.

Loss of MECP2 Affects the Transcriptome of Neurons {#sec2.2}
--------------------------------------------------

It has been suggested that loss of MECP2 only affects gene expression in neurons as opposed to the hPSCs and NPCs from which they were derived ([@bib13]). We sought to determine whether gene expression was affected in hiPSCs, NPCs, or neurons in this patient-derived *in vitro* model. To optimize the search for molecular effects of loss of MECP2 in neurons, we generated defined neuronal cultures by following the newly established 3i (three inhibitor) method to create interneurons ([Figure 2](#fig2){ref-type="fig"}A) ([@bib20]). Interneurons are particularly relevant in the study of Rett syndrome as interneuron-specific deletion of *Mecp2* in mice recapitulates many of the disease symptoms ([@bib11], [@bib33]). We validated the quality of differentiation at each step by immunostaining for markers typical of particular cell types (SOX2, SOX1, and NESTIN as well as FOXG1 and NKX2.1 for NPCs; and Tuj1, MAP2, and GABA for interneurons) in both WT and MUT cultures followed by quantification ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B). While methods for derivation from pluripotent stem cells are effective at making interneurons, these cultures are not pure. As such, we first ensured that the proportion of neurons present in the cultures for comparison were not consistently different ([Figure S4](#mmc1){ref-type="supplementary-material"}C). We then assessed whether interneurons lacking MECP2 also showed diminished dendritic branching. In fact, in patient-derived interneurons made by 3i, defects in dendritic branching as measured by the number of endpoints were clearly observed ([Figure 2](#fig2){ref-type="fig"}A).Figure 2Loss of MECP2 Is Associated with Differential Gene Expression in Neurons(A) Immunostaining neurons generated from patient 982 for TuJ1, a neuronal-specific marker. Right: quantification of dendritic complexity by counting endpoints.(B) Volcano plots of differentially expressed genes (DEGs) in hiPSCs, NPCs, and neurons.(C) Gene ontological analysis of DEGs increased versus decreased in MECP2 null neurons.(D) An examination of SASP genes in neurons.(E) Patient skin-derived clones of fibroblasts lacking MECP2 showed strong β-gal activity, while those of WT fibroblasts did not.(F) Top: the senescence assay applied to neural progenitors derived from Rett patients did not show significant senescence activity. Bottom: patient-derived neuronal cultures showed a strong increase in the absence of MECP2 (quantification across independent lines shown on the right).(G) RT-PCR for P53 targets after siRNA treatment of WT neurons.Bar graphs represent means ± SEM. ^∗^p \< 0.05. Scale bars on images indicate 10 μm.

We therefore proceeded with deep RNA sequencing (RNA-seq; \>120 million reads per sample) of hiPSC, NPC, and interneuron cultures. With such sequencing depth, it was possible to analyze the RNA-seq reads for the known mutations present in the patients from which these lines were made ([Figure S4](#mmc1){ref-type="supplementary-material"}D). This analysis demonstrated that each line studied expressed strictly either the WT or mutant allele of *MECP2*, and that XCI status was unchanged even after extensive differentiation to neurons. We quantified the expression level of *MECP2* in WT cells across these three stages of development and found that the average reads per kilobase of transcript per million mapped reads RPKM was 3.1 for hiPSCs, 4.3 for NPCs, and 7.75 for interneuron-enriched cultures. This is consistent with consensus that MECP2 is enriched in neuronal cells, but also demonstrates that it could potentially be relevant to hiPSC and NPC physiology as well. However, high stringency analyses (false discovery rate \<0.05) of the RNA-seq data yielded very few gene expression changes due to loss of MECP2 in hiPSCs or NPCs derived from Rett patients ([Figure 2](#fig2){ref-type="fig"}B), consistent with [@bib13]. On the other hand, interneuron cultures made from patient 982 showed many gene expression changes when comparing two individual WT and MUT clones ([Figure 2](#fig2){ref-type="fig"}B). Gene ontology analysis uncovered many neuronal physiology-related pathways that were downregulated due to loss of MECP2 in neurons, while genes associated with extracellular remodeling and cell migration appeared to be induced ([Figure 2](#fig2){ref-type="fig"}C).

Probing the RNA-seq data, we also found that MECP2 null interneuron cultures showed a strong increase in a group of genes that are known to be induced by senescent cells, known as the senescence-associated secretory program (SASP). The vast majority of SASP genes that were changed in MECP2 null neurons were upregulated as opposed to downregulated, suggesting a robust pattern of SASP induction ([Figure 2](#fig2){ref-type="fig"}D). The only previous report linking MECP2 loss to senescence was performed by partial silencing of this protein in mesenchymal stem cells, but the results were consistent with those shown here for patient-derived MECP2 null fibroblasts ([@bib29]). The induction of SASP was intriguing in light of the fact that, while attempting to make clones of fibroblasts from patients with Rett syndrome, we repeatedly found that clones lacking MECP2 did not expand well after passage (14 MECP2 null clones were created, none expanded), while clones expressing the WT allele expanded without a problem (42 MECP2+ clones were created, we attempted to expand four of them, and all four expanded).

To determine whether MECP2 null fibroblasts encounter senescence, we performed an assay to detect endogenous beta-galactosidase activity, which is known to be a hallmark of this process ([@bib36]). Indeed, MECP2 null fibroblasts showed strong activity in this senescence assay ([Figure 2](#fig2){ref-type="fig"}E). We did not encounter such difficulties with clonal expansion once hiPSCs or hiPSC-derived NPCs were made from patients, presumably because during reprogramming, telomerase is strongly induced to restore telomere length at least beyond the critical threshold ([@bib19], [@bib30]). In fact, our RNA-seq data showed that hiPSCs made from patients had very high expression of *TERT*, and NPCs still expressed moderate levels, while neurons did not express appreciable levels (average RPKM for *TERT*: hiPSC, 8.8; NPC, 1.6; neuron, 0.006). Importantly, the same endogenous galactosidase activity assay on interneurons showed a dramatic increase in senescence activity in neurons lacking MECP2 ([Figure 2](#fig2){ref-type="fig"}F). These data indicate that loss of MECP2 leads to not only induction of SASP but also a *bona fide* senescence program in neurons.

Induction of P53 in the Absence of MECP2 {#sec2.3}
----------------------------------------

Cellular senescence programs are known to be regulated by P53, which can then activate various response pathways downstream, such as DNA repair and apoptosis ([@bib34]). Interestingly, P53 induction due to telomere shortening was previously shown to cause defects in dendritic branching ([@bib7]), which is also the dominant phenotype in Rett syndrome. To begin to look for hallmarks of P53 induction in the absence of MECP2, we performed RT-PCR for P53-related targets in cells with silencing of *MECP2* by siRNA ([Figure S4](#mmc1){ref-type="supplementary-material"}E). This assay suggested that decreased MECP2 levels led to induction of P53-related target genes such as *P21*, *GADD45*, *DDIT4*, and *DDB2* ([Figure 2](#fig2){ref-type="fig"}G).

To determine the effect of loss of MECP2 in relation to cell-stress pathways at the protein level, we performed immunostaining for H2AX, PML, P53, and P21 in neurons with and without MECP2. Staining for each of these markers showed strong increases in expression/levels of these markers of cell stress in patient-derived NPCs, neurons, and also after silencing of *MECP2* in both NPCs and neurons ([Figures 3](#fig3){ref-type="fig"}A--3D). WT NPCs with silencing of *MECP2* by siRNA and neurons lacking MECP2 also showed clear induction of these marks.Figure 3Loss of MECP2 Leads to Induction of DNA Damage and P53(A) Immunostaining of patient NPCs, NPCs with siRNA against MECP2, and patient neurons showed a strong increase in H2aX in the absence of MECP2.(B) Immunostaining of patient NPCs, NPCs with siRNA against MECP2, and patient neurons.(C) Immunostaining for P53 and p21, a target of P53.(D) Immunostaining after siRNA silencing of MECP2 in WT neuronal cultures.(E) Treatment of MECP2 null neurons with DMSO or Pifithrin, followed by immunostaining with antibody for TuJ1 shows a change in dendritic branching. Bottom left: RT-PCR for *GADD45*, a P53 target gene, showed that Pifithrin reduced P53 activity. Bottom right: quantification of branching phenotype across three independent experiments.^∗^p \< 0.05 according to Student\'s t test. Bar graphs represent means ± SEM. Scale bars on images indicate 10 μm.

Blocking Induction of P53 Can Rescue Dendritic Branching Defects Due to Loss of MECP2 {#sec2.4}
-------------------------------------------------------------------------------------

Previous evidence from a murine model of telomere shortening as a result of loss of telomerase complex (TERT) led to defects in dendritic branching, and this effect was strictly dependent on induction of P53 ([@bib7]). A more recent study also showed that experimentally aging the neural lineage with telomerase inhibition led to neurons with signs of aging, including reduced dendritic branching ([@bib35]). Therefore, we posited that inhibition of P53 in MECP2 null neurons could potentially restore appropriate dendritic branching. To determine whether blocking the action of P53 could improve dendritic branching in MECP2 null interneurons, we took advantage of Pifithrin-α, a potent inhibitor of P53 target gene activation ([@bib1]). Treatment of MECP2 null interneurons with Pifithrin-α showed evidence of P53 inhibition as measured by RT-PCR for *GADD45* ([@bib34]), a target gene important for DNA repair ([Figure 3](#fig3){ref-type="fig"}E). After 24--48 hr of P53 inhibition by Pifithrin-α, MECP2 null interneurons appeared to adopt an improved neuronal morphology typified by increased physical distinction between the soma and neurites, longer, thinner neurites, as well as increased dendritic branching as shown and quantified in [Figure 3](#fig3){ref-type="fig"}E. These data provide evidence that neurons without MECP2 induce P53 activity, which then inhibits the formation of complex neuronal processes.

To determine whether any of the phenotypes discovered in this *in vitro* model of Rett syndrome have relevance to patients afflicted with the disease, we acquired tissue specimens from Rett patients and age-matched controls. We first quantified the degree of chimerism of female Rett patient neurons due to skewing of X chromosome inactivation to determine the relative ratio of neurons that express MECP2 versus those that did not. Some of the Rett patient brains showed roughly 75% of neurons lacked MECP2, while others appeared to have less than 25% MECP2 null neurons ([Figure 4](#fig4){ref-type="fig"}A).Figure 4Evidence for P53 Induction in Rett Patient Neurons in Human Brain(A) Each Rett brain sample was assessed for the percentage of neurons with and without expression of MECP2 by immunostaining.(B) RT-PCR on RNA isolated from Rett brain versus age-matched control brains for P53 targets.(C) A re-analysis of data published by [@bib8]. Shown are a sample of P53 targets and SASP genes found on lists of genes upregulated in Rett brain. All of these differentially expressed genes were derived using a corrected p value (false discovery rate) \<0.05 from at least n = 5 samples from control and Rett brains.Bar graphs represent means ± SEM.

We performed RT-PCR on samples from some of these brains to determine whether they showed signs of increased P53 activity. To ensure accurate RNA representation, we first assessed the quality of the RNA from these frozen tissues, and only proceeded with RT-PCR in samples that showed an RIN (RNA integrity number) value above 5. All the Rett patient brains we processed for RT-PCR showed induction of canonical P53 target genes (identified in [@bib37]), consistent with what was observed in the patient-derived neurons *in vitro* ([Figure 4](#fig4){ref-type="fig"}B). Recently, a new study was published that isolated brain tissue from Rett patients and control subjects to perform an RNA-seq profile to characterize changes specific to Rett motor cortex or cerebellum. Using data provided in that study, we found that many direct P53 targets (as defined in [@bib37]) and SASP signature genes were upregulated in the Rett brains in both the motor cortex and the cerebellum ([Figure 4](#fig4){ref-type="fig"}C).

Discussion {#sec3}
==========

Taken together, these data demonstrate that loss of MECP2 leads to clear signs of stress such as H2AX deposition, P53/P21 induction, and initiation of a senescence program, all of which suggest that neurons in Rett syndrome could be in suboptimal health, leading to neurophysiological defects such as dendritic arborization ([@bib41]). While one paper suggested that RNAi-mediated silencing of *MECP2* could promote senescence in mesenchymal cells ([@bib29]), decades of work on Rett syndrome have not uncovered a role for MECP2 in relation to senescence in a wide variety of models such as various transgenic mouse lines, human patient postmortem analyses, and *in vitro* human models.

These results also raise the question of whether senescence could be common to the etiologies of other intellectual disability syndromes. The phenotypes described here show a striking similarity to those observed in hiPSCs and neural derivatives made from patients with immunodeficiency, centromeric region instability, and facial anomalies syndrome (ICF) syndrome ([@bib40]). Two independent studies showed that ICF patient-derived hiPSCs displayed telomere shortening that was coupled to senescence of somatic derivatives such as fibroblasts. ICF syndrome only partially overlaps with Rett syndrome in terms of patient phenotypes, but is caused by mutations in DNMT3B, a *de novo* DNA methyltransferase ([@bib15]). These findings together are highly relevant as DNMT3B is a key *de novo* methyl transferase to create methylated DNA (5mC), which is the substrate for Tet oxygenase's to create 5-hydroxmethylated DNA (5hmC), which is known to be strongly bound by MECP2 ([@bib23]). Recently, another study showed that deletion of Tet enzymes, which are critical to generate the 5hmC mark, led to shortened telomeres ([@bib39]), which is known to lead to P53 activation.

Another possible interpretation of these data is that instead of a failure to mature, Rett syndrome neurons instead show aspects of premature aging. The fact that MECP2 null neurons show induction of aging-related genes, including P53 targets, and induce senescence pathways are consistent with this idea ([@bib31]). On the other hand, while Rett patients suffer from a post-natal cognitive decline, and long-term survivors show phenotypes associated with Parkinson disease ([@bib42]), the typical phenotypes presented in young female patients are not consistent with premature aging. Whether the physiological response to loss of MECP2 is truly akin to premature aging or whether patients suffer from effects that are unrelated to aging is worthy of continued investigation.

Experimental Procedures {#sec4}
=======================

Generation of Isogenic Rett Syndrome iPSCs {#sec4.1}
------------------------------------------

Reprogramming was performed as described ([@bib16]).

Generation of Teratomas {#sec4.2}
-----------------------

Generation of teratomas was previously described ([@bib14]).

Differentiation *In Vitro* and Analysis {#sec4.3}
---------------------------------------

Neural specification with neural rosette derivation, neuroprogenitor (NPC) purification, and further differentiation to neurons and glia were performed as described previously ([@bib26], [@bib27]).

Immunofluorescence and Image Quantification {#sec4.4}
-------------------------------------------

Immunofluorescence was performed as described previously ([@bib27]) and is described in detail in the [Supplemental Information](#mmc1){ref-type="supplementary-material"}.

RT-qPCR {#sec4.5}
-------

RT-PCR with real-time PCR measurement was carried out on a Roche 480 as described ([@bib26], [@bib27]). The primer sequences are available in the [Supplemental Information](#app2){ref-type="sec"}.

siRNA Gene Silencing {#sec4.6}
--------------------

All knockdown experiments were performed as described previously ([@bib27]).

β-Galactosidase Senescence Assay {#sec4.7}
--------------------------------

β-Galactosidase senescence assay was performed using the Senescence β-Galactosidase Staining Kit from Cell Signaling. The number of blue cells and number of total cells were quantified using the Cell Counter plugin in ImageJ.

Quantification of Dendritic Arborization {#sec4.8}
----------------------------------------

The stained cells were then imaged at 20×, and dendritic arbors of individual cells were traced using the Simple Neurite Tracer plugin for ImageJ. The number of process ends per cell were counted using the Cell Counter plugin for ImageJ. The number of process ends per cell are presented as mean ends per cell ± SEM.

RNA Expression Profiling {#sec4.9}
------------------------

RNA-seq was performed as described previously ([@bib9]). These data are available from NIH dataset GEO: [GSE107399](ncbi-geo:GSE107399){#intref0010}.
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